



## NOXXON PHARMA HOSTS KEY OPINION LEADER SYMPOSIUM

**Berlin, Germany, 20 January 2016, NOXXON Pharma AG** (“NOXXON” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on cancer treatment development, today announces that the Company hosted a Key Opinion Leader symposium focused on current advances in the treatment of multiple myeloma. The symposium focused on the relevance of the tumor microenvironment in multiple myeloma, including the role of the CXCL12/CXCR4/CXCR7 axis, as well as an overview of key developments from The American Society of Hematology (ASH) Annual Conference.

The meeting featured keynote presentations by the following Key Opinion Leaders:

**Kenneth C. Anderson, MD** Kraft Family Professor of Medicine at Harvard Medical School, Director of Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, Director of the LeBow Institute for Myeloma Therapeutics and Vice President of ASH 2015. He also serves as the Kraft Family Professor of Medicine and Vice Chair of the Joint Program in Transfusion Medicine at Harvard Medical School. Dr. Anderson earned his medical degree from Johns Hopkins School of Medicine, where he also completed his residency, and completed his fellowship in medical oncology at DFCI.

Dr. Anderson has received several prestigious awards including the ASH William Dameshek Prize as well as awards from organizations such as the International Myeloma Foundation, American Association for Cancer Research, and the American Cancer Society. He is currently a member of the Johns Hopkins Society of Scholars, the Institute of Medicine of the National Academy of Sciences, and the Royal Colleges of Physicians and of Pathologists in the United Kingdom.

**Irene Ghobrial, MD** is the attending Physician, Medical Oncology at Dana-Farber Cancer Institute, Associate Professor of Medicine and Harvard Medical School and Director, Michele & Stephen Kirsch Laboratory.

**Aram Mangasarian, PhD, Chief Executive Officer of NOXXON Pharma, commented:** *“There is an increasing body of evidence which points towards the critical role that the tumor microenvironment plays in how cancer tumors grow and spread. Our unique Spiegelmer<sup>®</sup> platform has generated a broad proprietary pipeline of clinical-stage assets, including our lead product candidate, NOX-A12, which are able to target the tumor microenvironment and therefore have the potential to significantly enhance the effectiveness of current cancer treatments. We are pleased to have gathered such a prestigious group of experts to discuss advances in this area.”*

**For more information, please contact:**

**NOXXON Pharma AG**

Aram Mangasarian, PhD, Chief Executive Officer  
Tel. +49 (0) 30 726 2470  
[amangasarian@noxxon.com](mailto:amangasarian@noxxon.com)

**Consilium Strategic Communications**

Chris Gardner, Mary-Jane Elliott, Jonathan Birt, Lindsey Neville and Hendrik Thys  
Tel. +44 (0) 203 709 5708  
[noxxon@consilium-comms.com](mailto:noxxon@consilium-comms.com)

**HuijskensBickerton**

Ian Bickerton and Andrew Beh  
Tel. +31 (0) 20 685 5955  
[ian@huijskensbickerton.com](mailto:ian@huijskensbickerton.com)

**NewCap**

Pierre Laurent, Emmanuel Huynh, Florent Alba and Tristan Roquet Montegon  
Tel. +33 (0) 14 471 9497  
[pl Laurent@newcap.fr](mailto:pl Laurent@newcap.fr)

**MC Services**

Dorothea Schneider and Raimund Gabriel  
Tel. +49 (0) 89 2102 2860  
[dorothea.schneider@mc-services.eu](mailto:dorothea.schneider@mc-services.eu)

**About NOXXON**

NOXXON Pharma AG is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON is using its proprietary class of drugs, "Spiegelmers", to target the tumor microenvironment, the new frontier in cancer treatment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON's Spiegelmer<sup>®</sup> platform has generated a broad proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB and NGN. NOXXON has its statutory seat and its office in Berlin, Germany. Further information can be found at: [www.noxxon.com](http://www.noxxon.com).